Trials / Terminated
TerminatedNCT01032291
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cetuximab | Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle. |
| DRUG | lenalidomide | Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-12-15
- Last updated
- 2013-05-21
- Results posted
- 2013-05-21
Locations
17 sites across 6 countries: Australia, Belgium, Germany, Italy, Spain, Sweden
Source: ClinicalTrials.gov record NCT01032291. Inclusion in this directory is not an endorsement.